🇺🇸 FDA
Pipeline program

Lebrikizumab, MOMETASONE , Placebo for Lebrikizumab

J2T-MC-KGBU

Phase 3 small_molecule active

Quick answer

Lebrikizumab, MOMETASONE , Placebo for Lebrikizumab for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly Co.
Indication
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials